August 14, 2019
Published by Sean Leach at August 14, 2019
Categories
Proof of Concept trial results for Staccato Alprazolam has neurology community cautiously optimistic
Speed of onset action is encouraging; additional research on other epilepsy patient subsets an important next step. Read more here: https://journals.lww.com/neurotodayonline/Pages/articleviewer.aspx?year=2019&issue=08080&article=00009&type=Fulltext
August 2, 2019
Published by Sean Leach at August 2, 2019
Categories
Greg Mayes, Engage Therapeutics’ CEO and Founder, will join other Life Science Intelligence leaders at the Ritz Carlton Laguna Niguel in Dana Point, CA February 18 […]
July 9, 2019
Published by Sean Leach at July 9, 2019
Categories
This proof-of-concept study referenced in this peer-reviewed journal demonstrated that three doses of Staccato alprazolam (0.5 mg, 1.0 mg, and 2.0 mg) rapidly suppressed epileptic activity […]
July 1, 2019
Published by Sean Leach at July 1, 2019
Categories
Greg discusses his personal connection to epilepsy and the challenges his company faces in finding the perfect study participants for the clinical trial of Staccato Alprazolam, […]
July 1, 2019
Published by Sean Leach at July 1, 2019
Categories
MIAMI, July 01, 2019 (GLOBE NEWSWIRE) — New York Times bestselling author Kurt Eichenwald will be at the Mayfair Hotel and Spa in Coconut Grove on […]
May 6, 2019
Published by Engage Therapeutics at May 6, 2019
Categories
Eight (8) patients with predictable generalized or focal epileptic seizures treated with Staccato alprazolam 62.5 percent of patients respond with cessation of seizure activity within two […]
March 13, 2019
Published by Engage Therapeutics at March 13, 2019
Categories
SUMMIT, N.J., March 11, 2019 /PRNewswire/ — Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a Rapid Epileptic Seizure Termination (REST) therapy for people who experience […]
February 11, 2019
Published by Engage Therapeutics at February 11, 2019
Categories
International Epilepsy Day is here! With individuals and organizations sharing stories of taking action, we thought we’d take the opportunity to reflect on what the team […]
December 3, 2018
Published by Engage Therapeutics at December 3, 2018
Categories
On December, 3, 2018, Engage Therapeutics announced at the American Epilepsy Society’s Annual Meeting the successful completion of the open label portion of the StATES (Staccato […]
October 22, 2018
Published by Engage Therapeutics at October 22, 2018
Categories
Engage Therapeutics board member is named one of TIME’s “The Health Care 50” for epilepsy research: Health Care 50 | Time.com